AR075631A1 - Composiciones farmaceuticas que comprenden un compuesto que tiene efecto supresor en la digestion o absorcion de nutrientes y un derivado de ciclohexancarboxamida - Google Patents
Composiciones farmaceuticas que comprenden un compuesto que tiene efecto supresor en la digestion o absorcion de nutrientes y un derivado de ciclohexancarboxamidaInfo
- Publication number
- AR075631A1 AR075631A1 ARP100100582A ARP100100582A AR075631A1 AR 075631 A1 AR075631 A1 AR 075631A1 AR P100100582 A ARP100100582 A AR P100100582A AR P100100582 A ARP100100582 A AR P100100582A AR 075631 A1 AR075631 A1 AR 075631A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- obesity
- substituted
- pharmaceutical composition
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 230000029087 digestion Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 235000015097 nutrients Nutrition 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 6
- 235000020824 obesity Nutrition 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000008035 Back Pain Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 201000001498 Froelich syndrome Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000008930 Low Back Pain Diseases 0.000 abstract 1
- 208000019255 Menstrual disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102000019280 Pancreatic lipases Human genes 0.000 abstract 1
- 108050006759 Pancreatic lipases Proteins 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 1
- 229960001243 orlistat Drugs 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229940116369 pancreatic lipase Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009045369 | 2009-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075631A1 true AR075631A1 (es) | 2011-04-20 |
Family
ID=42665505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100582A AR075631A1 (es) | 2009-02-27 | 2010-02-26 | Composiciones farmaceuticas que comprenden un compuesto que tiene efecto supresor en la digestion o absorcion de nutrientes y un derivado de ciclohexancarboxamida |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR075631A1 (ja) |
| TW (1) | TW201032805A (ja) |
| WO (1) | WO2010098298A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011058943A1 (ja) * | 2009-11-11 | 2011-05-19 | 塩野義製薬株式会社 | Ｍｃｈ ｒ１アンタゴニスト活性を有する化合物とｎｐｙ ｙ５受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物 |
| WO2013002313A1 (ja) * | 2011-06-29 | 2013-01-03 | 塩野義製薬株式会社 | 体重管理薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2389681C (en) * | 1999-11-26 | 2010-11-02 | Shionogi & Co., Ltd. | Npy y5 antagonist |
| RU2004129285A (ru) * | 2002-02-28 | 2005-10-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные тиазола в качестве антагонистов рецептора npy |
| AU2003253925A1 (en) * | 2002-07-18 | 2004-02-09 | Banyu Pharmaceutical Co., Ltd. | Combination therapy for the treatment of obesity |
| CN100381429C (zh) * | 2002-08-07 | 2008-04-16 | 霍夫曼-拉罗奇有限公司 | 噻唑衍生物 |
| CA2555409A1 (en) * | 2004-02-19 | 2005-09-01 | Banyu Pharmaceutical Co., Ltd. | Novel sulfone amide derivative |
| EP2062878A4 (en) * | 2006-08-30 | 2010-09-08 | Shionogi & Co | HYDRAZINE AMIDE DERIVATIVE |
-
2010
- 2010-02-23 WO PCT/JP2010/052677 patent/WO2010098298A1/ja not_active Ceased
- 2010-02-26 AR ARP100100582A patent/AR075631A1/es not_active Application Discontinuation
- 2010-02-26 TW TW099105552A patent/TW201032805A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201032805A (en) | 2010-09-16 |
| WO2010098298A1 (ja) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067326A1 (es) | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido | |
| Emir et al. | Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML | |
| EP3634430A1 (en) | Multibiotic agents and methods of using the same | |
| MX2011007544A (es) | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. | |
| BR112013014914A2 (pt) | composto, composição farmacêutica, método de tratar câncer em um paciente e uso | |
| MX2009003305A (es) | Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso. | |
| EA201100266A1 (ru) | Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные | |
| EA201100910A1 (ru) | Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих | |
| EA201290957A1 (ru) | Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения | |
| MY157828A (en) | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions | |
| ATE524450T1 (de) | 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren | |
| GT200600193A (es) | Imidazoquinolines como inhibidores de lipidos kinase | |
| EA201200975A1 (ru) | Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение | |
| DK1909600T3 (da) | Sammensætning til moderering af alkoholmetabolisme og til at reducere risikoen for alkoholforårsagede sygdomme | |
| WO2008029217A3 (en) | Dipeptidyl peptidase iv inhibitors | |
| CO6410283A2 (es) | Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas | |
| Xu et al. | Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors | |
| ECSP066883A (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes | |
| MX2010001352A (es) | Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares. | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| PH12013501117A1 (en) | Novel compound and medical use thereof | |
| AR075631A1 (es) | Composiciones farmaceuticas que comprenden un compuesto que tiene efecto supresor en la digestion o absorcion de nutrientes y un derivado de ciclohexancarboxamida | |
| Choi et al. | Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells | |
| Han et al. | Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity | |
| WO2010079413A3 (en) | Dipeptidyl peptidase iv inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |